OrphoMed is a clinical-stage biotechnology company with a proprietary dimer therapeutics platform. The company is focused on developing best-in class treatments for patients with gastrointestinal disorders.
Member count: 11-50
Total raised: $39M
Founded date: 2015
Investors 2
| Date | Name | Website |
| 06.07.2021 | New Enterp... | nea.com |
| - | Takeda Ven... | takeda.com |
Funding Rounds 1
| Date | Series | Amount | Investors | Deal News |
| 24.05.2017 | Series A | $39M | New Enterp... | citybizlis... |
Mentions in press and media 4
| Date | Title | Description | Category | Author | Source |
| 25.05.2017 | Term Sheet... | FIGHTS, CRYPTO-CORNS Investor... | - | - | fortune.co... |
| 24.05.2017 | OrphoMed S... | SAN FRANCISCO, CA, Clinical ... | - | - | vcnewsdail... |
| 24.05.2017 | NEA Leads ... | OrphoMed, Inc., a clinical sta... | - | - | citybizlis... |
| 24.05.2017 | OrphoMed R... | OrphoMed, Inc., a San Francisc... | USA | - | finsmes.co... |